Trends in Oral Anticoagulation Therapy Among Korean Patients With Atrial Fibrillation: The KORean Atrial Fibrillation Investigation

다국어 초록 (Multilingual Abstract)

Background and Objectives: Anticoagulation with vitamin K antagonists (VKAs) such as warfarin provides effective stroke prophylaxis in patients with atrial fibrillation (AF). We conducted a large multicenter survey of Korean patients with AF to determine trends in VKA use.
Subjects and Methods: Eligible patients were adults with AF that had been prescribed VKAs. Medical records from a total of 5616 patients {mean age 63.6±12.2 years, male 3150 (56.1%)} in 27 hospitals from Jan. 2001 to Oct. 2007 were reviewed.
Results: The mean international normalized ratio (INR) was 2.04±0.64, and mean dosage of VKA was 3.66±1.50 mg. Individuals in their sixties (1852 patients) accounted for about one third of patients studied. As patients grew older, INR increased and VKA dosage decreased.
The dosage of VKA in male patients was larger than that in females for all ages. A total of 2146 (42.4%) patients had an INR of 2-3, and less than 40% patients in their sixties had an INR within optimal range. The dosage of oral anticoagulant for optimal INR level was 3.71 mg.
Conclusion: In this study, less than half of the Korean patients with AF on VKA reached the therapeutic range of INR. Mean dosage of VKA was 3.66±1.50 mg, and the dosage of oral anticoagulant for optimal INR level was 3.71 mg, which decreased with age.

참고문헌 (Reference)

1 김영훈, "심방 세동의 약물 치료와 침습적 치료" 대한심장학회 33 (33): 553-558, 2003

2 Ansell J, "The pharmacology and management of the vitamin K antagonists: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy" 126 (126): 204S-233S, 2004

3 Laupacis A, "Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: analysis of pooled data from five randomized controlled trials" 154 : 1449-1457, 1994

4 Miura T, "Relationship between aging and dosage of warfarin: the current status of warfarin anticoagulant therapy for Japanese outpatients in a department of cardiovascular medicine" 53 : 355-360, 2009

5 이광수, "Prevalence of Atrial Fibrillation in Middle-Aged People in Korea: The Korean Genome and Epidemiology Study" 대한심장학회 38 (38): 601-605, 2008

6 Atarashi H, "Present status of anticoagulation treatment in Japanese patients with atrial fibrillation: a report from the J-RHYTHM Resistry" 75 : 1328-1333, 2011

7 Lip GY, "Oral anticoagulation in atrial fibrillation: a pan-European patient survey" 18 : 202-208, 2007

8 van Walraven C, "Oral anticoagulants vs aspirin in nonvalvular atrial fibrillation: an individual patient meta-analysis" 288 : 2441-2448, 2002

9 Yasaka M, "Optimal intensity of international normalized ratio in warfarin therapy for secondary prevention of stroke in patients with non-valvular atrial fibrillation" 40 : 1183-1188, 2001

10 Waldo AL, "Hospitalized patients with atrial fibrillation and a high risk of stroke are not being provided with adequate anticoagulation" 46 : 1729-1736, 2005

11 Stansbury JP, "Ethnic disparities in stroke: epidemiology, acute care, and postacute outcomes" 36 : 374-386, 2005

12 van Walraven C, "Effect of study setting on anticoagulation control: a systematic review and metaregression" 129 : 1155-1166, 2006

13 Shen AY, "Effect of race/ethnicity on the efficacy of warfarin: potential implications for prevention of stroke in patients with atrial fibrillation" 22 : 815-825, 2008

14 Hylek EM, "Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation" 349 : 1019-1026, 2003

15 Wolf PA, "Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study" 147 : 1561-1564, 1987

16 Singer DE, "Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)" 133 (133): 545S-592S, 2008

17 Fuster V, "2011 ACCF/AHA/HRS focused updates incorporated into the ACC/AHA/ESC 2006 Guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in partnership with the European Society of Cardiology and in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society" 57 : e101-e198, 2011